Table 1 Functions of SEs in chemoresistance
From: Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance
Directions | Cancer | Resistant drugs | Induction methods | SE related genes | References |
|---|---|---|---|---|---|
Related genes downstream | Ovarian cancer | Cisplatin | Stepwise method | SOX9 → WNT5A | [45] |
SCLC | Doxorubicin, cisplatin, etoposide | De novo | IRF1 → MYB, SP1 → ABCC1 | [116] | |
BRAF-mutant colon cancer | Vemurafenib | De novo | MAPK pathway | [139] | |
MCL | Ibrutinib, lenalidomide | / | BCR pathway, IKZF-MYC axis | [140] | |
TNBC | Neoadjuvant chemotherapy | De novo | MYCN | [141] | |
NSCLC | TRAIL, cisplatin | De novo | c-FLIP, XIAP | [142] | |
HCC | Sorafenib | / | ZNF263 | [143] | |
CSCs | Pancreatic adenocarcinoma | Gemcitabine | De novo | RORγ | [117] |
Ovarian cancer | Cisplatin | Cisplatin IC20 | ALDH | [119] | |
Squamous cell carcinoma | Cisplatin | Cisplatin IC50 | SOX2 + →SOX9+ | [120] | |
Breast cancer | Salinomycin | De novo | / | [121] | |
ncRNAs | Pan-cancer | / | De novo | Linc00152 | [148] |
Prostate cancer | Enzalutamide | / | CHPT1 | [149] | |
Prostate cancer | / | / | MANCR | [150] | |
Colorectal cancer | Oxaliplatin | 2 μM oxaliplatin | MALAT1 | [152] | |
Microenvironment | Clear cell renal cell carcinoma | / | / | CXC | [134] |
Squamous cell carcinoma | / | / | CXCL1/2 | [161] | |
Pancreatic ductal adenocarcinoma | / | / | / | [135] | |
Cellular plasticity | Breast cancer | / | / | EN1, TBX18, TCF4 | [131] |
Basal cell carcinoma | Vismodegib | De novo | Vismodegib and Wnt pathway | [132] |